

VICKI L. GROO

833 S. Wood St. (M/C 886)
Chicago, IL 60612

Office: 312-413-0928
Email: vjust@uic.edu

Licensure: Illinois 051-037179 / Ohio # 03-1-16296

Education

1986-1988 Doctor of Pharmacy
The Ohio State University, Columbus, Ohio

1981-1985 Bachelor of Science, Pharmacy
The University of Toledo, Toledo, Ohio

Professional Experience

2004-present Clinical Pharmacist, Ambulatory Care
Practice Site - Congestive Heart Failure Program
University of Illinois @ Chicago, Chicago, Illinois

1989-present Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois @ Chicago, Chicago, Illinois

2001-2003 Clinical Pharmacist – Congestive Heart Failure Program
Clinical Pharmacist – Coumadin and Lipid Point of Care Clinic
Dr. Randall E. Williams, Director
Evanston Northwestern Healthcare, Evanston, Illinois

1999-2001 Clinical Pharmacist/Research Coordinator
Medpak Cardiology, LLC--Dr. Mary Anne Papp, Director
Michael Reese Hospital, Chicago, Illinois

1998-1999 Clinical Team Leader-Cardiology
Michael Reese Hospital
Owen Healthcare, Inc. Chicago, Illinois

1989-1998 Clinical Pharmacist
Coronary & Medical Intensive Care
VA West Side Medical Center, Chicago, Illinois

1988-1989 Advanced Pharmacy Resident
Cardiology and Critical Care
University of Illinois @ Chicago, Chicago, Illinois

Teaching Experience

Preceptor: University of Illinois Cardiovascular Pharmacotherapy Fellowship/PGY2 residency

Preceptor: PGY1 Pharmacy Practice Residency at each hospital listed above

Preceptor: UIC Doctor of Pharmacy Students

Instructor: UIC Doctor of Pharmacy Students, Core Pharmacotherapy Curriculum

Faculty: Ambulatory Pharmaceutical Care Certificate Program

Research

Co-Investigator: Telepharmacy Robotic Medicine Delivery Unit “TRMDU” Sponsor: Department of Defense (DOD) Telemedicine and Advanced Technology Research Center (TATRC). Role: Data analysis and interpretation. (proposal in start-up phase)

Co-Investigator. Compliance with dual antiplatelet therapy following percutaneous coronary intervention with a drug-eluting stent: A prospective evaluation. PI: Dr. Shroff (in-progress)

Co-Investigator. Torsemide vs. Furosemide Plus Metolazone for Symptomatic Chronic Heart Failure (in-progress) PI: Beth Greenhalgh

Preceptor: University of Illinois Pharmacy Practice Residency Project 2007-2008. Late-Onset Hyperkalemia Associated with use of Spironolactone in Heart Failure Patients.

Co-Investigator/Study Coordinator. Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT—in progress). Sponsor: NHLBI, funded/ PI: Dr Stamos

Co-Investigator. Determinants of Cardiac Fibrosis and Spironolactone Response in Heart Failure. (in progress)

Co-Investigator/Study Coordinator. Randomized Evaluation of Long-term anticoagulant therapy (RE-LY) Sponsor: Boehringer Ingelheim, funded/ PI: Dr Stamos

Co-Investigator. A clinical trial comparing cangrelor to clopidogrel in subjects with acute coronary syndromes who are to be managed with percutaneous coronary intervention (CHAMPION-PCI)

Co-Investigator. A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention (CHAMPION-Platform)

Preceptor: University of Illinois Pharmacy Practice Residency Project 2005-2006. A retrospective review of the effect of low-dose aldosterone antagonists on loop diuretic dosing in the treatment of heart failure

Principal Investigator. ADHERE Longitudinal Module – Registry of Severe Heart Failure Patients at High Risk for Rehospitalization. Sponsor Scios Inc. funded

Preceptor: University of Illinois Pharmacy Practice Residency Project 2004-2005. Racial Differences in the Prevalence of Atrial Fibrillation in Heart Failure: A Retrospective Review

Co-investigator/study coordinator. A Double-Blind, Randomized Comparator-Controlled Study in Subjects with Type II Diabetes Mellitus Comparing the Effects of Pioglitazone HCL Versus Glimperide on the Rate of Progression of Atherosclerotic Disease as Measured by Intravascular Ultrasound. (PERISCOPE)

Co-investigator/study coordinator. Management of Patients with CHF After Hospitalization – Follow Up Serial Infusions of Natreacor – FUSION 1, a Pilot Study.

Co-investigator/study coordinator. Kansas City Cardiomyopathy Questionnaire Interpretability Study.

Co-investigator/study coordinator. (OVERTURE) Omapatrilat versus enalapril randomization trial of utility in reducing events.

Co-investigator/study coordinator: The 2nd SYMPHONY Trial. A phase III, multicenter, international, randomized, double-blind, aspirin-controlled trial to evaluate the efficacy and safety of two regimens with Xubix™ (sibrafiban, Ro 48-3657), an oral platelet glycoprotein IIb/IIIa receptor antagonist, as therapy for the long term prevention of secondary vascular events in patients after an Acute Coronary Syndrome.

Co-investigator: Theophylline in Renal Insufficiency: Effect on Contrast Induced Nephropathy.

Co-investigator/study coordinator: Sibrafiban Versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post Acute Coronary Syndromes.

Co-investigator/study coordinator: Prospective Randomized Amlodipine Survival Evaluation-2.

Co-investigator: Assessment of the Safety and Efficacy of a New Thrombolytic Agent: ASSENT II.

Co-investigator/study coordinator: A Randomized, Double-Blind Evaluation of the Efficacy and Safety of Two Dosing Regimens of Integrelin Versus Placebo for Reducing Mortality and Myocardial (Re)Infarction in Patients with Unstable Angina or Non-Q-Wave Myocardial Infarction (PURSUIT study).

Preceptor: VA West Side Pharmacy Resident Project, Evaluation of a mandatory formulary change from Procardia XL to Plendil or Norvasc.

Co-investigator/study coordinator: Evaluation of the Efficacy and Safety of Candesartan Cilexetil in the Treatment of Patients with Hypertension: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study.

Co-investigator: Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter.

Study coordinator: Prospective Randomized Amlodipine Survival Evaluation (PRAISE).

Co-investigator: Evaluation of Bioavailability of Enalapril in Severe Congestive Heart Failure.

Publications

Cavallari LH, **Groo VL**, Viana MA, Dai Y, Patel SR, Stamos TD. Circulating aldosterone and mineralocorticoid receptor genotype are predictive of potassium elevations with spironolactone in heart failure. [Submitted]

Shroff A, Ali A, Lee T, **Groo, VL**. Clopidogril Adherence Following Percutaneous Coronary Intervention with a Drug-Eluting Stent in a VA Medical Center. J Pharm Technol 2009;25:164-8.

Cavallari LH, **Groo VL**, Momary KM, Stamos TD, Vaitkus PT. Markers of cardiac collagen turnover are similar in patients with mild and more severe symptoms of heart failure. CHF. 2007;13:275-279.

Cavallari LH, Momary KM, **Groo VL**, Viana, MAG, Camp JR, Stamos TD. β -blocker dose is associated with serum procollagen concentrations and cardiac response to spironolactone in heart failure. Pharmacotherapy 2007 June;27(6):801-812.

Cavallari LH, **Groo VL**, Momary KM, Fontana D, Viana MA, Vaitkus P. Racial difference in potassium response to spironolactone in heart failure. Congestive Heart Failure 2006;12(4): 200-205.

Cavallari LH, Vaitkus P, **Groo V**. Hyperkalemia after the Publication of Rales—Correspondence. N Engl J Med 2004;351(23): 2448-2450.

Cavallari LH, Fashingbauer LA, Beitelshes AL, **Groo VL**, Southworth, MR, Viana MAG, Williams RE, Dunlap SH. Racial Differences in Patients' Potassium Concentrations During Spironolactone Therapy for Heart Failure. Pharmacotherapy 2004;24(6):750-756.

Kumar AN, Choudary G, Antonio C, **Just VL**, Heaney L, Papp MA. Carvedilol Titration in Class IIIb and IV

CHF Patients on Stabilized on Inotropic Therapy. *American Heart Journal* 2001;142(3): 512-515.

Phillips BG, Gandhi AJ, Sanoski CA, **Just VL**, Bauman JL. Comparison of Intravenous Diltiazem and Verapamil for the Acute Treatment of Atrial Fibrillation and Atrial Flutter. *Pharmacotherapy* 1997;17(6): 1238-1245.

Just VL, Schrader BJ, Paloucek FP, Hoon TJ, Leikin JB, Bauman JL. An Evaluation of Drug Therapy for Treatment of Hypertensive Urgencies in the Emergency Department. *Am J Emergency Med* 1991;9: 107-111.

Abstracts/Presentations

Cavallari LH, **Groo VL**, Viana MA, Dai Y, Patel SR, Stamos TD. Circulating aldosterone and mineralocorticoid receptor genotype are predictive of potassium response to spironolactone in heart failure. *Pharmacotherapy* 2008; 10(28):120e (#18). Available through www.pharmacotherapy.org. Platform presentation at the 2008 Annual Meeting of the American College of Clinical Pharmacy. Louisville, KY. October 2008.

Basuray A, Gordon RA, Ferrara D, Mezgarzedeh, Mohamedali B, Groo V, Fontana D, Stamos T. Patient reported symptom activity scale and correlation to the six minute walk test in an outpatient heart failure population. *J Card Failure* 2008;14;S107 (#352)

Goodwin H, **Groo V**, Cavallari L, Stamos T. Late onset hyperkalemia with spironolactone therapy. *J Cardiac Fail* 2008; 14(6):S113 (#372). Poster presentation at the 12th Annual Scientific meeting of the Heart Failure Society of America. Toronto, ON, Canada. September 2008.

Hoeksema J, Cavallari L, **Groo V**, Avitall B, Gonzalez R. Effect of aldosterone antagonists on shock frequency with implantable cardioverter defibrillators. *J Cardiac Fail* 2008; 14(6):S75 (#240). Poster presentation at the 12th Annual Scientific meeting of the Heart Failure Society of America. Toronto, ON, Canada. September 2008.

Cavallari LH, **Groo VL**, Patel S, Viana MAG, Stamos TD. Circulating aldosterone is predictive of potassium elevations with spironolactone in heart failure. *J Cardiac Fail* 2008; 14(6):S74 (#235). Poster presentation at the 12th Annual Scientific meeting of the Heart Failure Society of America. Toronto, ON, Canada. September 21-24, 2008.

Cavallari LH, **Groo VL**, Viana, MA, Camp JR, Stamos TD. Angiotensinogen haplotype and potassium response to spironolactone. *Clin Pharmacol Ther* 2008; 83 (Suppl 1):S81 (#P111-31). Poster presentation at 2008 American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL. April 2-5, 2008.

Mesgarzedah P, **Groo VL**, Fontana D, Stamos TD. Long term outcomes in hospitalizations for acute decompensated heart failure in patients followed in a multidisciplinary heart failure clinic compared to those in a general cardiology clinic. Poster presentation at American Heart Association Quality of Care and Outcomes Research, Washington DC. May 2007.

Groo VL, Mohrman C, Fontana D, Stamos TD. Switching from metoprolol to carvedilol results in improved blood pressure control in patients with heart failure. *Pharmacotherapy* 2007;27 (10). Platform presentation at the 2007 Annual Meeting of the American College of Clinical Pharmacy. Denver, CO. October 15, 2007.

Cavallari LH, **Groo VL**, Momary KM, Stamos TD. Angiotensinogen diplotype and spironolactone response in heart failure. *J Cardiac Fail* 2007;13(6):S100 (#253). Poster presentation at the 11th Annual Scientific Meeting of the Heart Failure Society of America. Washington, DC. September 2007.

Cavallari LH, Groo VL, Stamos TD. Markers of cardiac fibrosis are similar in African Americans and Caucasians with heart failure. J Cardiac Failure 2007;13(6):S100 (#091). Poster presentation at the 11th Annual Scientific Meeting of the Heart Failure Society of America. Washington, DC. September 2007.

Momary KM, Groo VL, Stamos TD, Camp JR, Cavallari LH. Beta-blocker dose influences cardiac response to spironolactone in heart failure. Pharmacotherapy 2006; 26:e55 (#40). Poster presentation at the 2006 Annual Meeting of the American College of Clinical Pharmacy. St. Louis, MO. October 2006. ***First runner-up in the Best Student, Resident, Fellow Paper Award Competition.*

Ali A, Shroff AR, Lee T, Groo VL. Evaluation of compliance with clopidogrel therapy post PCI in a VA Hospital. Pharmacotherapy 2006; 26:e55(358). Poster presentation at the 2006 Annual Meeting of the American College of Clinical Pharmacy. St Louis, MO. October 2006.

Perez A, Cavallari LH, Fontana D, Stamos TD, Groo VL. Low dose aldosterone antagonism reduces diuretic requirements in heart failure. J of Cardiac Failure 2006:12(6) suppl:S118. Poster presentation at Heart Failure Society of America 10th Annual Scientific Meeting, September 2006, Seattle, Washington

Groo VL, Momary KM, Stamos TD, Camp J, Cavallari LH. Serum Procollagen Peptides are Similar in Mildly and Severely Symptomatic Patients with Heart Failure. J of Cardiac Failure 2006:12(6) suppl:S32. Poster presentation at Heart Failure Society of America 10th Annual Scientific Meeting, September 2006, Seattle, Washington.

Agusala P, Fontana D, DiDomenico R, Groo V, Stamos TD, Vaitkus PT. The effects of nesiritide and other vasoactive agents on renal function. J of Cardiac Failure 2006:12(6) suppl:S88. Poster presentation at Heart Failure Society of America 10th Annual Scientific Meeting, September 2006, Seattle, Washington.

Mesgarzadeh P, Groo VL, Fontana D, Stamos TD. Guideline Adherence is Improved in Patients Followed in a Multidisciplinary Heart Failure Clinic Compared to Those in A General Cardiology Clinic, Poster presentation at American Heart Association Quality of Care and Outcomes Research. Washington DC, May 2006.

Krueger C, Rene L, Momary K, Groo V, Fontana D, Vaitkus P, Cavallari L. Dietary potassium intake and potassium use with spironolactone. Pharmacotherapy 2005; 25(10): 1437 (#44). Poster presentation at the 2005 Annual Meeting of the American College of Clinical Pharmacy, October 2005. San Francisco, CA.

Master H, Groo V, Cavallari L, Shroff A. Racial differences in the prevalence of atrial fibrillation in heart failure: a retrospective review. Pharmacotherapy 2005; 25 (10). Poster presentation at the 2005 Annual Meeting of the American College of Clinical Pharmacy, October 2005, San Francisco, CA.

Cavallari LH, Fashingbauer LA, Groo V, Southworth MR, Fontana D, Williams RE, Vaitkus P. Racial differences in potassium response to spironolactone. Pharmacotherapy 2004;24(10):1423-1424 (#24). Platform presentation at the 2004 Annual Meeting of the American College of Clinical Pharmacy. October 26, 2004, Dallas, TX.

Groo VL, Williams RE. Improving Safety Monitoring of Amiodarone in the Congestive Heart Failure Population: Assessment of a Chart Reminder System. J of Cardiac Failure 2003:9(5) suppl:S106. Poster presentation at Heart Failure Society of America 7th Annual Scientific Meeting, September 2003, Las Vegas, Nevada.

Groo VL, Moyer-Knox, D, Mueller TM, Vuckovic K, Williams, RE. Effectiveness of Toprol XL[®] in Heart Failure Patients Intolerant to Coreg.[®] J of Cardiac Failure 2003:9(5) suppl:S96. Poster presentation at Heart Failure Society of America 7th Annual Scientific Meeting, September 2003, Las Vegas, Nevada.

Humma LM, Fashingbauer LA, Beitelshes AL, **Just VL**, Southworth MR, Williams RE, Dunlap S. Effects of Race and Gender on Potassium Requirements with Spironolactone Therapy in Heart Failure. J of Cardiac Failure 2002;8(4) suppl:S60. Poster presentation at Heart Failure Society of America 6th Annual Scientific Meeting, September 2002, Boca Raton, Florida.

Knox DA, Mueller TM, Vuckovic KM, Acker KJ, Mischke LE, **Just VL**, Williams RE. Remote Titration of Beta-blocker Therapy for Heart Failure by Advanced Practice Nurses, Titration Protocols and Daily Patient Telemanagement. J of Cardiac Failure 2002;8(4) suppl:S83. Poster presentation at Heart Failure Society of America 6th Annual Scientific Meeting, September 2002, Boca Raton, Florida.

Just VL, Williams RE. Improving the Safety of Amiodarone in the Congestive Heart Failure Population: Baseline Assessment of Compliance with National Guidelines in a Large CHF Clinic. J of International Society for Pharmacoeconomics and Outcomes Research 2002;5(3):126. Oral presentation at ISPOR 7th Annual International Meeting, May 2002, Arlington, Virginia.

Choudhary G, Fayn E, Vrushab R, Kumbar C, Antonio C, **Just V**, Clark WA, Papp MA. Intermittent Milrinone and Beta-Blocker Therapy: Hemodynamic (Bio-Z.com) Indicators of Successful Weaning from Inotropes. J of Cardiac Failure 2000;6(3) suppl 2:79. Poster presentation at Heart Failure Society of America 4th Annual Scientific Meeting, September 2000, Boca Raton, Florida.

Just V, Antonio C, Kumbar C, Papp MA. Milrinone Assisted B-blocker Titration: Long-term Follow-up. J of Heart Failure 2000;6(1):118. Oral presentation at International Society of Heart Failure 7th World Congress, July 2000, Vancouver, B.C., Canada.

Kumbar C, Choudhary G, Vrushab R, Fayn E, Antonio C, **Just V**, Clark WA, Papp MA. Outpatient Infusion of Positive Inotropes: Role of Bioimpedence, Noninvasive Hemodynamic Monitoring (Bio-Z). J of Heart Failure 2000;6(1):48. Poster presentation at International Society of Heart Failure 7th World Congress, July 2000, Vancouver, B.C., Canada.

Kumar AN, Heaney L, Choudary G, Antonio C, **Just V**, Denes P, Papp MA. Carvedilol Titration in Class IIIb/IV Heart Failure – Role of Inotropic Support. J of Cardiac Failure 1999;5(3) suppl 1:52. Poster presentation at Heart Failure Society of America 3rd Annual Scientific Meeting, September 1999, San Francisco, California.

Haydek M, Furmaga EM, **Just VL**. Outcome of a Mandatory Formulary Conversion of Nifedipine XL to Felodipine in a Veterans Affairs Medical Center. Am J Hypertension 1997;10:141A. Poster presentation at American Society of Hypertension, May 1997, San Francisco, California.

Oberg KC, **Just VL**, Bauman JL, Papp MA. Reduced Bioavailability of Enalapril in Patients with Severe Heart Failure (abstr). J Am Coll Cardiol 1994; Feb: 381A. Poster presentation at American College of Cardiology, March 1994, Atlanta, Georgia.

Just VL, Schrader BJ, Paloucek FP, Hoon TJ, Leikin JB, Bauman JL. An Evaluation of Drug Therapy for Treatment of Hypertensive Urgencies in the Emergency Room (abstr). Pharmacotherapy 1989;9:176. Platform presentation at American College of Clinical Pharmacy, August 1989, Kansas City, Missouri.

Invited Presentations

Using Multidisciplinary Teams to Implement Evidenced Based Medicine – One Centers Experience. July 2007. International Research Nursing Conference Focusing on Evidence Based Practice. Vienna, Austria

Aldosterone Antagonists in Heart Failure: Beyond RALES. February 2007 University of Illinois Cardiology Grand Rounds.

Management of Chronic Heart Failure. September 2006 Illinois Council of Health-System Pharmacists Fall Meeting, Oak Brook, Illinois

ADHF: Is Calcium Sensitization the Answer? December 2005 University of Illinois Cardiology Grand Rounds.

An Update on Therapy for Heart Failure: Focus on Beta-Blockers. October 2003 Pharmacy Week Education Program.

Update on Thrombolytic Therapy. November 1999, University of Illinois, Continuing Education Program, Chicago, Illinois.

Acute Coronary Syndrome Workshop. July 1998, Owen Healthcare Annual Meeting, St. Louis, Missouri.

Controversies in Cardiology. March 1998, Illinois Pharmacy Spring Congress Closing Session, Springfield Illinois.

Hyperlipidemia and Secondary Prevention: How Low Should We Go? May 1996, University of Illinois Department of Medicine Grand Rounds, Chicago, Illinois.

Conducting Multi-Center Trials: Our Experience with "PRAISE" April 1996, University of Illinois Department of Medicine Journal Club, Chicago, Illinois.

The Pharmacology of Medications Used in the Treatment of Bronchospasm, December 1991, Nursing Continuing Education, VA West Side Medical Center, Chicago, Illinois.

Catecholamines and Vasodilators in Intensive Care, May, 1990, Basic Critical Care Nursing, VA West Side Medical Center, Chicago, Illinois.

Other Professional Activities

APhA Lipid Management Certification January 2009

APHA Immunization Certification May 2008

ACCP Heart Failure Traineeship Instructor (May 2008-present)

Presenter, Chicago Department of Aging monthly "Pharmacist Talk" (March 2007-December 2007)

Consultant, Inrange Systems (2002-present)

Carvedilol Advisory Panel, Glaxo Smith Kline (Oct 2005 - 2008)

Levosimendan Advisory Board, Abbott Labs (2004-2006)

Nesiritide Advisory Panel, Scios Inc. (2003)

Cardiology Advisory Board, Owen Healthcare (1998-1999).

Reviewer: Angina and Other Reversible Ischemic Syndromes in Pharmacotherapy Self-Assessment Program 2nd ed. Module 1.

Reviewer: Pharmacotherapeutics: Clinical Reasoning in Primary Care 2/e Chapter 42 (Diuretics) Chapter 38 (Antilipemic Drugs) Elsevier Publishing